labgeni.us valid
LabGenius Therapeutics
ML-driven Antibody Discovery
- Authority
- 46 reach 5 · trust 5 · quality 21 · freshness 15
- Tier
- listed
- llms.txt
- https://labgeni.us/llms.txt
- Sections
- 8
- Links
- 94
- Size
- 29250 bytes
- Popularity rank
- #993452
- Country
- United States Country-code domain
- Hosting country
- United States Hosting inference
- Country evidence
- No published address evidence collected yet
- First seen
- 2026-10-25T18:12:15.185Z
- Last checked
- 2026-10-26T11:40:47.286Z
- Badge
Their llms.txt
The beginning of the file, from our validated copy saved 2026-10-26T11:40:46.341Z. Cached copy · Source on labgeni.us
Generated by All in One SEO Pro v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.
# LabGenius Therapeutics
ML-driven Antibody Discovery
## Sitemaps
- [XML Sitemap](https://dev-labgenius.pantheonsite.io/sitemap.xml): Contains all public & indexable URLs for this website.
## Posts
- [News](https://dev-labgenius.pantheonsite.io/news/) - Explore the latest news, events, and publications from LabGenius Therapeutics. Stay informed on how AI, robotics, and synthetic biology are transforming antibody drug discovery.
- [Article | Beyond binder design: why AI's next frontier is designing multispecific antibodies](https://dev-labgenius.pantheonsite.io/article-beyond-binder-design-why-ais-next-frontier-is-designing-multispecific-antibodies/)
- [Article | Right On-Target: Developing Safe and Selective Multispecific T-Cell Engagers](https://dev-labgenius.pantheonsite.io/article-right-on-target-developing-safe-and-selective-multispecific-t-cell-engagers/)
- [Article | Programming biology: next-gen AI firms raise billions to design better medicines](https://dev-labgenius.pantheonsite.io/article-programming-biology-next-gen-ai-firms-raise-billions-to-design-better-medicines/)
- [Press release | LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes](https://dev-labgenius.pantheonsite.io/sanofi/) - ● The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA™) to optimise potential therapeutic NANOBODY® proteins for multiple new targets. LONDON, United Kingdom — December 4, 2025. LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential
- [Press release | LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody](https://dev-labgenius.pantheonsite.io/press-release-lgchem/) - The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform, EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit
- [Press release | LabGenius Therapeutics Announces Poster Presentation at the AACR Annual Meeting 2026](https://dev-labgenius.pantheonsite.io/press-release-labgenius-therapeutics-announces-poster-presentation-at-the-aacr-annual-meeting-2026/) - LONDON, United Kingdom — March 17, 2026. LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI), high-throughput experimentation and machine-learning to discover next-generation therapeutic antibodies, today announced
…Machine-readable: GET /v1/resolve?q=labgeni.us · GET /v1/domain/labgeni.us · this page as Accept: application/json or text/markdown · MCP lookup_domain
Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.
Own or manage this website?
If you own or manage labgeni.us, you can update its listing and review file health, discovery activity and score history.
Manage this listing — optional
What verification unlocks
See how your site is discovered—and control what agents see.
- See your website in the map
Review your indexed topics, nearby publishers sharing headings, measured listing exposure and map snapshots in a private report for your website.
- Control what agents see
Edit your listing description, tags, public contact details and additional llms.txt paths. Publish your terms for automated access, attribution and pricing.
- Make your profile eligible for search
A valid, listed, unblocked, verified profile can appear in our publisher sitemap and become eligible for search-engine visibility. Search engines decide what to index and rank.
- Appear in our llms-full.txt
Eligible verified publishers are listed by name, with their file links and summaries, in the service overview agents can read.
Free. No account registration, backlink or payment required. Public discovery remains available without verification.
Let your coding agent verify it
If your coding agent is authorized to manage this website, paste these instructions into it.
Claim my listing on Agent Web Map for labgeni.us:
1. POST https://agentwebmap.com/v1/sites/labgeni.us/claims and keep claim_id and claim_secret private.
2. Publish the verification line "AgentWebMap verification: <token>" (token from step 1) in https://labgeni.us/llms.txt, or use the DNS, meta-tag or well-known method the response describes. This only verifies the listing; your website and domain remain yours.
3. POST https://agentwebmap.com/v1/sites/labgeni.us/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/labgeni.us).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verifyCorrections or removal requests: contact the directory.